Insilico Medicine vs Owkin
Relationship
inClinico and BiomarkerPlus do comparable work on drug discovery; similar scale (private); ships AI agent and data service rather than the same layer.
Assembled from the recorded fields for this pair, not hand-checked. The comparison below is read from each company’s own profile.
3 of 8 capabilities — Shares data analysis, drug discovery and knowledge retrieval.
Ludbee capability tags · from the product recordsDifferent layer — Owkin ships AI agent and data service, not the same layer.
Ludbee product recordsAligned comparison
Capability overlap
Shared · 3
Not verified for Owkin · 5
Recorded for Insilico Medicine. Owkin’s product records say nothing either way — a missing record is not a missing capability.
Owkin has no capability Insilico Medicine lacks, among the 3 recorded here.
Products, side by side
Algorithmic pairing — assembled from recorded fields, not hand-checked
Insilico Medicine
No shared stack layer with the other side.
Owkin
No shared stack layer with the other side.
No counterpart
Insilico Medicine sells these in a stack layer with no product recorded for Owkin yet — nothing on the other side to compare them against.
Application
AI research writing assistant that drafts structured, cited papers, reviews, grant proposals and abstracts against biomedical databases such as PubMed and bioRxiv.
Multimodal AI platform that forecasts the probability of success of individual clinical trials and scores alternative trial designs before implementation.
Platform
AI platform for de novo design and multi-property optimization of peptides, nanobodies and antibodies against specified targets and epitopes.
Generative small-molecule design platform combining de novo generation with physics-based methods, retrosynthesis, ADMET profiling and custom model training.
Foundation-model training and benchmarking platform that fine-tunes a customer's own LLM on Insilico's proprietary pharma reasoning datasets and validates results in its automation lab.
AI platform for therapeutic target identification, biomarker discovery, indication prioritization and drug repurposing over a multi-omics knowledge base.
End-to-end generative-AI platform spanning target discovery, molecular design and clinical-trial risk assessment for pharmaceutical research.
Hardware
On-premise AI appliance running PandaOmics target and biomarker discovery locally with no external data transmission, sold in Server and Desktop editions.
Owkin sells these in a stack layer with no product recorded for Insilico Medicine yet — nothing on the other side to compare them against.
AI agent
Research agent that answers biomedical questions across Owkin's clinical and molecular datasets.
Data service
Multimodal AI-derived spatial biomarkers, developed with pharmaceutical partners to inform drug discovery and patient stratification.